A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome

• Register: EUCTR
• Last refreshed on: 19 April 2022
• Main ID: EUCTR2017-001219-35-NL
• Date of registration: 29/11/2017
• Prospective Registration: Yes
• Primary sponsor: Cortendo AB
• Public title: A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome
• Scientific title: A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
• Date of first enrolment: 24/05/2018
• Target sample size: 54
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001219-35
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes; Randomised: yes; Open: no; Single blind: no; Double blind: yes; Parallel group: no; Cross over: no; Other: no; If controlled, specify comparator, Other Medicinial Product: no; Placebo: yes; Other: no; Number of treatment arms in the trial: 2
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Bulgaria, Denmark, France, Greece, Hungary, Israel, Italy, Netherlands, Poland, Romania, Spain, United States

Contacts

• Name: Clinical Trial Information
• Affiliation: Cortendo AB

• Name: Clinical Trial Information
• Affiliation: Cortendo AB

Key inclusion & exclusion criteria

Inclusion criteria:
The following categories of potential subjects, categorized by prior use of levoketoconazole, may be eligible if the following 11 inclusion criteria are all met:
- Naïve to levoketoconazole;
- Completers of SONICS visit M12 who are not currently on levoketoconazole (i.e. not actively receiving open label treatment after SONICS as part of EAP or OLE study);
1. Male or female and at least 18 years of age.
2. Able and willing to provide written informed consent
3. Confirmed newly diagnosed, persistent or recurrent endogenous Cushing’s syndrome of any etiology, except secondary to malignancy (including pituitary or adrenal carcinoma). Persistence will not be considered confirmed until 6 weeks or more post-surgery
4. Elevated mean 24 hour UFC levels at least 1.5X ULN of the normative range of the study’s central laboratory assay and from a minimum of three measurements from adequately collected urine; the study’s central laboratory must be used for all qualifying measurements.
NOTE: This criterion does not apply to subjects currently on levoketoconazole.
5. Presence of abnormal values from at least one of these two diagnostic tests (discrepancies between test findings will not be investigated nor considered exclusionary):
• Abnormal Dexamethasone Suppression Test (DST): Elevated 8 AM blood cortisol at least 1.8 µg/dL (50 nmol/L) after 1 mg dexamethasone orally at 11 PM the evening prior with concurrent dexamethasone blood concentration greater than 5.6 nmol/liter (220 ng/dL) (results from within the 2 months prior to start of Screening or newly tested with results available by the Baseline Visit [TM0]) OR
• Elevated LNSC concentrations (at least two measurements) each greater than the ULN of the study’s central laboratory normative range; the study’s test kit and lab must be used for all qualifying measurements.
NOTE: Abnormal LNSC is required among eligible subjects with estimated glomerular filtration rate (eGFR as determined by Modified Diet in Renal Disease MDRD equation) above 40 and below 60 mL/min/1.73 m2 .
NOTE: This criterion does not apply to subjects currently on levoketoconazole.
6. Non-candidates for CS-specific surgery, refuse surgery or surgery will be delayed until after study completion and agree to complete this study prior to surgery.
7. If post-surgical for CS-specific surgery, then no significant post operative sequelae remain and the risk of such sequelae is considered negligible.
8. Agree to the following minimum washout periods prior to the Baseline Visit (TM0) (as applicable):
• Ketoconazole or metyrapone: 2 weeks;
• Dopamine agonists: bromocriptine (2 weeks), cabergoline (8 weeks);
• Octreotide acetate LAR, lanreotide Autogel®, pasireotide LAR: 12 weeks;
• Lanreotide SR: 8 weeks;
• Octreotide acetate (immediate release) or short-acting pasireotide: 1 week;
• Mifepristone (RU 486, KORLYM®): 4 weeks;
• Megestrol acetate or medroxyprogesterone acetate (and selected other synthetic progestins): 6 weeks.
9. Females who are either of non-child bearing potential (i.e. incapable of becoming pregnant):
• Post-menopausal, defined as age 50 or older with amenorrhea for more than 1 year or any age with serum follicle stimulating hormone (FSH) at least 23 mIU/mL and estradiol no more than 40 pg/mL (140 pmol/L) OR
• Surgically sterile—documented hysterectomy and/or bilateral oophorectomy or tubal ligation.
OR
• Females of child-bearing potential who agree to use highly effective methods of birth
Exclusion criteria:
Subjects will be excluded from the study if ANY of the following criteria are met:
1.Enrolled or early terminated from SONICS or currently on levoketoconazole
2.Pseudo-Cushing's syndrome based on Investigator assessment
3.Cyclic Cushing's syndrome with multi-week periods of apparent spontaneous CS remission
4.Non-endogenous source of hypercortisolism, including pharmacological corticosteroids or ACTH
5.Radiotherapy of any modality directed against the source of hypercortisolism within the last 5 years
6.Treatment with mitotane within 6 months of enrolment
7.History of malignancy, including adrenal or pituitary carcinomas (other than low risk, well-differentiated carcinomas of thyroid, breast or prostate that are very unlikely to require further treatment in the opinion of the treating physician, or squamous cell or basal cell carcinoma of the skin)
8.Clinical or radiological signs of compression of optic chiasm
9.Major surgery within 1 month of Screening (or within 6 weeks for pituitary surgery)
10.Clinically significant abnormality in 12-lead ECG during the Screening Phase requiring medical intervention
11.QTc interval above 470 msec during the Screening Phase via central reader interpretation
12.History of Torsades des Pointes, ventricular tachycardia, ventricular fibrillation, history of prolonged QT syndrome
13.Use of medications associated with possible, probable, or definite QT/QTc prolongation
14.Pre-existing hepatic disease
15.Hepatitis B surface antigen (HbsAg) or hepatitis C-positive
16.Human immunodeficiency virus (HIV)-positive.
17.History of symptomatic cholelithiasis with intact gallbladder
18.History of pancreatitis
19.Liver safety tests during the Screening Phase as follows:
-ALT and/or AST above 3X ULN
-Alkaline phosphatase or total bilirubin above 2X ULN Subjects with isolated indirect bilirubin up to 3X ULN are presumed to have Gilbert's syndrome & may be enrolled if all other liver tests are within normal levels
20.History of documented or suspected drug-induced liver injury to ketoconazole or any other azole drug
21.Serum potassium below 4.0 mEq/L
22.Abnormal FT4, unless subsequently corrected and stable for at least 4 weeks. Subjects with TSH less than the LLN and normal FT4 are potentially eligible without intervention
23.History of persistent uncontrolled hypertension
24.Hypercholesterolemia currently treated with atorvastatin, lovastatin or simvastatin and unwilling or unable to change to alternative therapy with: pravastatin, fluvastatin, pitavastatin or rosuvastatin (must switch statin at least 2 weeks prior to dosing) or another allowed therapy. For subjects for whom lipid reduction therapy is considered, all lipid lowering drugs should be added and stabilized for at least 4 weeks prior to TM0 for the levoketoconazole-naïve cohort, as improvements in lipids are being assessed as an endpoint for levoketoconazole treatment
25.More than one hospitalization for hyperglycemia or complication of diabetes during the last 12 months
26.Decreased renal function as defined by eGFR below 40 mL/min/1.73m2, using MDRD equation for eGFR
27.Pregnant or lactating
28.Body habitus preventing repeated venipuncture as required by protocol
29.Any other clinically significant medical condition, as determined by the Investigator that precludes enrollment and participation in the study through completion, including conditions that would preclude the subject from being able to follow instructions or pe

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]

Endogenous Cushing´s syndrome (CS)
MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860

Intervention(s)

Product Name: levoketoconazole
Product Code: COR-003
Pharmaceutical Form: Tablet
INN or Proposed INN: levoketozonazole
CAS Number: 142128-57-2
Current Sponsor code: COR-003
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Primary Outcome(s)

Main Objective: To determine the effect of withdrawing to placebo versus continuing treatment with levoketoconazole on the cortisol therapeutic response previously established during open-label levoketoconazole therapy.

Secondary Objective: To compare the effects of levoketoconazole with placebo on:
1 cortisol status during Randomized Withdrawal & Restoration Phases
2 changes in biomarkers of CS comorbidities
3 changes in health related quality of life & depression;
4 changes in acne, hirsutism & peripheral edema
5 To assess levoketoconazole safety & tolerability
6 To evaluate the population pharmacokinetics of levoketoconazole in CS subjects
NOTE:Secondary Objectives 5 & 6 are not subjects of hypothesis tests Exploratory Objectives:
1 To assess changes in anti-diabetic, anti-cholesterol, anti-hypertensive & chronic anti-inflammatory therapies
2 To describe effects & durations of levoketoconazole with respect to cortisol status & clinical signs & symptoms of CS other than acne, hirsutism & peripheral edema
3 To describe dose-response relationship of levoketoconazole with respect to safety & tolerability
4 To describe effects of levoketoconazole on glucose tolerance among subjects with impaired fasting glucose

Timepoint(s) of evaluation of this end point: Loss of therapeutic response is inferred based on the mean of three 24-hour UFC measurements (mUFC) obtained at any visit from second through final Randomized Withdrawal Phase visits (RW1 through RW5 inclusive)

Primary end point(s): Proportion of subjects with loss of therapeutic response to levoketoconazole upon withdrawing to placebo compared with the proportion of subjects with loss of therapeutic response upon continuing treatment with levoketoconazole. Loss of therapeutic response (i.e. relapse) is inferred based on mUFC from three 24-hour urinary free cortisol (UFC) measurements obtained at any visit from second through final Randomized Withdrawal Phase visits (RW1 through RW5 inclusive) when:
(1) mUFC is above 1.5X the ULN of the central laboratory’s reference range, OR
(2) mUFC is more than 40% above the baseline (RW0) value, if the RW0 value is above the ULN (i.e. >1.0X ULN) , OR
(3) an early rescue criterion is met

Secondary Outcome(s)

Timepoint(s) of evaluation of this end point: 1: at all post-Baseline visits through the final study visit (RES2)
2: at RES2
3: at the end of Randomized Withdrawal Phase
4-6: at all post-Baseline visits through the final study visit (RES2)
7-10: along the study
10: all post-Baseline visits
11: from baseline till first time of loss of response
12: from RW5 till first normalization of mUFC
13: from RW5 till first normalization of LNSC
14-15:at the end of Dose Titration and Maintenance Phase (TM7)
16: at RES2
17-18: at all post-Baseline visits through the final study visit (RES2)
19-22: along the study

Secondary end point(s): 1.Changes from Baseline (RW0) in mUFC and LNSC at all post-Baseline
visits with these assessments through the final study visit (RES2)-applies to Secondary Objective 1;
2.Proportion of subjects with normalization of mUFC at RES2-applies to Secondary Objective 1;
3.Proportion of subjects with normalization of mUFC at the end of
RW Phase-applies to Secondary Objective 1;
4.Changes from Baseline (RW0) in biomarkers of CS comorbidities
(fasting glucose, fasting insulin, homeostatic model assessment-insulin resistance, hemoglobin A1c, total cholesterol, low-density lipoproteincholesterol, and high-sensitivity C-reactive protein at all post-Baseline visits with these measurements through the final study visit (RES2)-applies to Secondary Objective 2;
5.Changes from Baseline (RW0) in health-related QoL and symptoms of depression at all post-Baseline visits with these assessments through the final study visit (RES2)-applies to Secondary Objective 3;
6.Changes from Baseline (RW0) in acne, hirsutism and peripheral edema at all post-Baseline visits with these assessments through the final study visit (RES2)-applies to Secondary Objective 4;
7.Incidence and severity of adverse events, particularly adverse events of special interest during levoketoconazole open-label therapy in the Dose-Titration and Maintenance Phase (levoketoconazole-naïve cohort) and during blinded therapy in the Randomized Withdrawal Phase and Restoration Phase (both cohorts)-applies to Secondary Objective 5.
Pharmacokinetic Endpoints and Pharmacokinetic/Pharmacodynamic
modeling:
8.Estimates of the following PK parameters: clearance, volume of
distribution, absorption rate constant, with associated between subject variability where feasible.These parameters will be used to calculate half-life, area under the concentration time curve and peak
concentration, if feasible-applies to Secondary Objective 6;
9.Estimates of the following pharmacodynamic parameters:
levoketoconazole concentration producing half maximal UFC suppression (IC50), maximal suppression of UFC (Imax) and associated estimates of between-subject variability. UFC concentrations in relation to dose and plasma exposure will be explored-applies to Secondary Objective 6.
Exploratory Endpoints:
10.Frequency of usage and changes from Baseline (RW0) in frequency of usage of anti-diabetic, anti-cholesterol, anti-hypertensive,and chronic anti-inflammatory therapies at all post-Baseline visits;changes in corresponding biomarkers accounting for changes in medication usage will also be explored-applies to Exploratory Objective 1;
11.Time from RW0 to first time of loss of response:
1)mUFC is above 1.5X the ULN of the central laboratory's reference
range, OR
2)mUFC is more than 40% above the RW0 value, if the RW0 value is
above the ULN (i.e. >1.0X ULN)2, OR
3)an early rescue criterion is met-applies to Exploratory Objective 2;
12.Time to first normalization of mUFC beginning from RW5 (subset with mUFC above 1.5X ULN at RW5)-applies to Exploratory Objective 2;
13.Time to first normalization of LNSC beginning from RW5 (subset with LNSC above ULN at RW5)-applies to Exploratory Objective 2;
14.Proportion of subjects with normalization of mUFC at the end of Dose Titration and Maintenance Phase (TM7)—applies to Exploratory Objective 2;
15.Proportion of subjects with either normalization of mUFC or partial
response (at least 50% decrease in mUFC) at the end of Dose Titration
and Maintenance Phase (TM7)-applies to Exploratory Objective 2;
16.Proportion of subjects with normalization of LNSC at RES2-applies to Exploratory Objective 2;
17.Changes from Baseline (RW0) in serum cortisol and adrenocorticotrophic hormone at all post-Baseline visits with these
assessments through the final study visit (RES2)-applies to Exploratory
Objective 2;
18.Changes from Baseline (RW0) in clinical signs and symptoms of CS
excluding acne, hirsutism and peripheral edema at all post-Baseline
visits with these assessments through the final study visit (RES2)-applies to Exploratory Objective 2;
19.Frequency and severity of common AEs and laboratory abnormalities in relation to dose of study drug administered at the time of the reported AE or laboratory abnormality-applies to Exploratory Objective 3;
20.Shifts from normality and concentration changes from Baseline
(RW0) in serum transaminases, alkaline phosphatase, and total bilirubin at all post-Baseline visits in relation to dose of study drug administered at the time of the shift or change-applies to Exploratory Objective 3;
21.Durations and changes in durations from Baseline (RW0) of the QT
interval corrected for heart rate (QTc) in relation to dose of study drug
administered proximal to the measurement-applies to Exploratory
Objective 3.
22.Change from Baseline in observed and derived glucose and insulin
parameters during oral glucose tolerance test in the subset of subjects
with IFG-applies to Exploratory Objective 4.

Secondary ID(s)

2017-001219-35-ES

COR-2017-01

Source(s) of Monetary Support

Cortendo AB

Ethics review

Status: Approved
Approval date: 24/05/2018
Contact:

Results

• Results available: Yes
• Date Posted: 06/02/2022
• Date Completed: 31/08/2020
• URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001219-35/results